Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Lundbeck to Begin Late-Stage Trials on Alzheimer’s Drug Mid-2013

Dec. 5 (Bloomberg) -- H. Lundbeck A/S Chief Executive Officer Ulf Wiinberg said the company will probably begin late-stage trials on its experimental treatment for Alzheimer’s disease in the middle of next year with or without a partner.

Wiinberg said in August the company was in talks with several potential partners for the drug, called AE58054, and that further testing may start as early as the end of this year.

“What we realized was that the priority for us was to develop the phase 3 plan,” Wiinberg said in an interview in London today. “We may or may not have a partner by the time we start.”

AE58054 targets 5-HT6 receptors in the areas of the brain associated with cognition, resulting in increased concentrations of chemicals that aid learning and memory processes. About 18 million people worldwide have Alzheimer’s disease, and the number may almost double to 34 million by 2025, according to the World Health Organization.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.